HK Stock Market Move | REMEGEN (09995) surged up by over 5%, the application for the listing of RC288 injection was accepted, institutions are optimistic about its global potential.

11:09 13/03/2026

Rongchang Biology (09995) rose by more than 5% again, as of the time of the report, it had risen by 4.41%, closing at HK$90, with a turnover of HK$152 million.

REMEGEN (09995) rose by more than 5%, rising by 4.41% as of the time of publication, reaching 90 Hong Kong dollars with a trading volume of 152 million Hong Kong dollars. In terms of news, REMEGEN's application for the listing of REMEGEN RC288 injection has been accepted by the NMPA. RC288 is a PSMA/B7H3 ADC independently developed by REMEGEN, and in preclinical studies, the drug has shown excellent anti-tumor activity and safety. Guotai Haitong released a research report stating that REMEGEN will enter a new growth phase starting in 2026, mainly benefiting from the listing and entry into medical insurance for new indications of RC18, RC48, and RC28; overseas indications for RC48 and RC18 will gradually be launched for sales starting in 2027, bringing in sales royalties for the company; the company has started licensing out multiple assets since 2025, with initial payments and milestones to be confirmed in the coming years, strengthening the financial statements; the newly entered global FIC pipeline CDCP1 ADC RC278 and B7H3/PSMA ADC RC288 have the potential for global competitiveness, possibly bringing opportunities for licensing out.

160 HEALTH (02656) Controlling shareholder voluntarily extends lock-up period

SH IND URBAN (00563) successfully acquired a plot of land located in Xuhui District, Shanghai, with an estimated investment of approximately 2.675 billion yuan.

EVER HARVEST GP (01549) announces expected annual net profit attributable to shareholders of approximately HK$7.7 million, turning losses into profits on a year-on-year basis.

160 HEALTH (02656) Controlling shareholder voluntarily extends lock-up period

SH IND URBAN (00563) successfully acquired a plot of land located in Xuhui District, Shanghai, with an estimated investment of approximately 2.675 billion yuan.

EVER HARVEST GP (01549) announces expected annual net profit attributable to shareholders of approximately HK$7.7 million, turning losses into profits on a year-on-year basis.